Physician profile
Hemlata Bhatia
NPI 1801811310
$4,334.49
in general payments reported to CMS, 2019-2025
25 companies · $772 in 2025
The $772 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $197 · 2021: $865 · 2022: $716 · 2023: $515 · 2024: $777 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,249.90 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $703.81 | 2020-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $563.31 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $393.81 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.36 | 2020-2025 | Jardiance |
| Amgen INC. | $212.47 | 2020-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $184.82 | 2022-2025 | Verquvo, Steglatro |
| Amarin Pharma, INC. | $84.98 | 2020-2021 | |
| Electromed, INC. | $76.39 | 2024 | Smartvest |
| Lilly USA, LLC | $63.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Kowa Pharmaceuticals America, INC. | $54.09 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.28 | 2025 | Xifaxan |
| Nabriva Therapeutics, Plc | $51.19 | 2021 | |
| Idorsia Pharmaceuticals US INC | $45.84 | 2023 | Quviviq |
| Lexicon Pharmaceuticals, INC. | $35.16 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $33.86 | 2021-2022 | |
| Esperion Therapeutics, INC. | $32.80 | 2021-2025 | Nexletol |
| Sun Pharmaceutical Industries INC. | $28.80 | 2021 | |
| Exact Sciences Corporation | $28.43 | 2025 | Cologuard Collection Kit |
| Mannkind Corporation | $26.98 | 2020-2021 | |
| Insulet Corporation | $24.42 | 2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $15.19 | 2024 | Eliquis |
| Boston Scientific Corporation | $14.85 | 2023 | Lux-Dx Insertable Cardiac Monitor |
| Alnylam Pharmaceuticals INC. | $14.54 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemlata Bhatia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.